LBBW raises target for Schott Pharma stock from EUR 22 to EUR 26.50

Published on 10/22/2026 at 12:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q3 revenue reached EUR 281.80 million, up 8.30 percent year over year. Schott Pharma stock costs EUR 25.75 on October 22, 2026 versus EUR 25.80.

Analyst views split on valuation

LBBW lifted its target from EUR 22.00 to EUR 26.50 on October 12, 2026.
Third-quarter revenue reached EUR 281.80 million, up 8.30 percent year over year.
Schott Pharma stock trades at EUR 25.75 at 12:46 p.m. CEST at Lang & Schwarz on October 22, 2026, 0.19 percent below the Xetra close of October 21, 2026.
Full-year results are scheduled for December 10, 2026.

Schwarzweiß-Reportagefoto einer Ampullen-Abfüllanlage mit Techniker — SCHOTT Pharma (DE000A3ENQ51) dokumentiert eine Ampullen-Abfüllanlage in dramatischer Schwarzweiß-Reportagefotografie mit einem Reinraumtechniker davor, Illustration mit AI erstellt.

Schott Pharma (ISIN DE000A3ENQ51) was trading at EUR 25.75 at Lang & Schwarz on October 22, 2026 at 12:46 p.m. CEST, down 0.19 percent versus the Xetra close of October 21, 2026 at EUR 25.80. Goldesel reported on October 12, 2026 that LBBW raised its target from EUR 22.00 to EUR 26.50 and kept its Buy rating.

Q3 growth meets margin pressure

Schott Pharma's third-quarter revenue reached EUR 281.80 million, up 8.30 percent at constant currencies and 10.00 percent on a reported basis. The figure came from the company's Q3 and nine-month earnings call, published on August 12, 2026, and carried by Yahoo Finance.

The same call showed quarterly EBITDA of EUR 75.00 million and a 26.80 percent margin, versus a 32.30 percent margin in the third quarter of fiscal 2025. Nine-month EBITDA reached EUR 205.30 million, down 3.80 percent from EUR 213.30 million a year earlier. Lower utilization in drug delivery systems, infrastructure costs and process optimization weighed on profitability.

What does the target mean?

The LBBW target is EUR 0.75 above the October 22 Lang & Schwarz price, while the target itself followed a rise from EUR 22.00. The view is not shared across the analyst community. Yahoo Finance reported on October 9, 2026 that Deutsche Bank cut its rating from Buy to Hold and raised its target from EUR 23.00 to EUR 25.00, citing valuation after a strong year-to-date increase.

Three dated stock events

On August 12, 2026, Schott Pharma reported EUR 281.80 million in third-quarter revenue and confirmed fiscal 2026 revenue growth guidance of 5.00 percent to 6.00 percent at constant currencies, according to Yahoo Finance. On October 9, 2026, Deutsche Bank moved the rating to Hold and set a EUR 25.00 target, according to Yahoo Finance. On October 12, 2026, LBBW raised its target to EUR 26.50 from EUR 22.00, according to Goldesel.

Dates for the next report

Schott Pharma's full-year fiscal 2026 results are scheduled for December 10, 2026, according to TradingView. The investor-relations page also lists the BNP Midcap CEO Conference for November 17, 2026, as a company event.

Stock stays near its yearly high

The finance profile places Schott Pharma's market capitalization at EUR 3.9 billion as of October 22, 2026. Its 52-week range is EUR 12.62 to EUR 26.05, putting the current euro quote EUR 0.30 below the high. The operating picture therefore combines revenue growth with a margin recovery task in drug delivery systems.

Schott Pharma was trading at EUR 25.75 at Lang & Schwarz on October 22, 2026 at 12:46 p.m. CEST, 0.19 percent below the Xetra close of October 21, 2026 at EUR 25.80. The further course of trading is shown by the continuously updated real-time quote of Schott Pharma stock.